PD-1 inhibitor combination therapy
This page covers all PD-1 inhibitor combination therapy drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting PD-1.
Targets
Phase 3 pipeline (1)
- L-DEP and PD-1 antibody · Beijing Friendship Hospital · Oncology
L-DEP and PD-1 antibody is a combination therapy that enhances anti-tumor immunity by blocking PD-1 checkpoint inhibition while L-DEP provides immunomodulatory support.
Patent intelligence
- pd 1 inhibitor combination therapy patent landscape — aggregated cliff calendar, attackable patents, originator estates